-
Add Beyaz and Lo Loestrin Fe to the list of birth control choices for U.S. women. Both oral contraceptives (OCs) received Food and Drug Administration (FDA) approval in late 2010.
-
-
The end of September, marking six months after President Obama signed into law the Patient Protection and Affordable Care Act, was the effective date for numerous provisions intended to expand patients' rights and coverage under private insurance.
-
Question: What is the evidence that two condoms may be used at once? Who does this? What are their reasons for doing this? What are the other things that can do done to prevent condom breakage?
-
Results from a long-term follow-up analysis of participants in the Women's Health Initiative (WHI) suggest that among postmenopausal women, use of estrogen plus progestin is associated with an increased incidence of breast cancers that are more advanced, and with a higher risk of deaths attributable to breast cancer.
-
The authors randomized women with objectively validated heavy menstrual bleeding (mean menstrual blood loss [MBL] of 80 mL or more per cycle, confirmed using the alkaline hematin methodology during two pretreatment cycles) to treatment with oral tranexamic acid 3.9 g/d or placebo for up to 5 days per cycle for 6 menstrual cycles.
-
The rate of sepsis with group b streptococcus (gbs) in neonates of colonized mothers is now less than 1%.
-
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
The authors enrolled women desiring postpartum use of a levonorgestrel-releasing intrauterine system in a randomized trial to determine whether use of the device would be higher when insertion occurred immediately postpartum rather than delaying placement to the standard postpartum visit.